All News
Analyst Group comments on AcouSort’s expanded cell therapy collaboration
Read the full comment (in Swedish) here: https://analystgroup.se/kommentarer/analyst-group-kommenterar-acousorts-utokade-cellterapisamarbete/.
Read MoreCEO Torsten Freltoft summarizes 2022
For AcouSort, 2022 was in many ways a good year. As the pandemic restrictions were lifted, we were able to intensify our important marketing work while strengthening our commercial organization
Read MoreExtended collaboration targeting cell therapies generates revenues of EUR 130,000 in 2023
In November 2022, AcouSort reported that the company had entered a collaboration with a global life science company active within the cell therapy field. The first part of the project
Read MoreAcouSort and BlueCell in commercial planning as the stem cell therapy project Blue4Therapy approaches completion
The Blue4Therapy project was initiated in May 2020 with the ambition to develop clinical applications in cell therapy and stem cell treatments – two areas with great commercial potential. Behind
Read MoreTwo of AcouSort’s board members and CEO acquire shares
AcouSort AB (publ) (“AcouSort” or the “Company”) today announces that founders and board members Thomas Laurell and Stefan Scheding as well as CEO Torsten Freltoft have acquired shares in the
Read MoreThe BioWings project creates new opportunities for large-scale production and exosome-based diagnostics
AcouSort and its collaborators are now finishing the 4-year BioWings project which has developed new thin-film materials generating the ultrasound necessary to move cells in AcouSort’s chips. The new materials
Read MoreAcouSort presents at Stora Aktiedagen in Stockholm, November 30, addressing current developments in the vibrant cell therapy space
On November 30, 2022, CEO Torsten Freltoft will present at Stora Aktiedagen in Stockholm. In his presentation, Torsten will talk about the company’s continuous advancements in the cell therapy space,
Read MoreAcouSort Interim Report Q3, 2022
Today, November 23, 2022, AcouSort is releasing its Interim Report for Q3, 2022. The report is available both in Swedish and English and can be found here AcouSort AB Q3
Read MoreAcouSort expands its cell therapy efforts and enters collaboration with global life science company
Cell therapy is an area where AcouSort sees great potential for the company’s technology. Initially, AcouSort aims at enabling the automation of cell therapy preparation with its AcouWash technology. In
Read MoreAcouSort to supply Lund University with unique pre-focusing technology to enable high precision cell separation
AcouSort has received an order from Lund University to develop and deliver a modified AcouWash2 system with a unique pre-focusing feature to enable high precision cell separation of circulating tumor
Read More